Physician profile
Patrick D Daley
NPI 1285624502
$3,273.45
in general payments reported to CMS, 2019-2025
32 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $242 · 2021: $451 · 2022: $673 · 2023: $295 · 2024: $333 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $423.16 | 2019-2024 | Prolia, Evenity, Tezspire |
| Glaxosmithkline, LLC. | $367.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $356.17 | 2021-2024 | Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $319.18 | 2019-2022 | |
| Novo Nordisk INC | $175.43 | 2019-2025 | Rybelsus, Ozempic |
| Philips North America LLC | $166.72 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $155.32 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $139.28 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.99 | 2019-2024 | Jardiance |
| Abbott Laboratories | $108.97 | 2019-2023 | Mitraclip |
| Radius Health, INC. | $99.18 | 2020-2025 | |
| Amarin Pharma, INC. | $76.53 | 2019-2021 | |
| Daiichi Sankyo INC. | $76.50 | 2019-2024 | Injectafer |
| Lilly USA, LLC | $69.62 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.97 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $62.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.46 | 2019-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $55.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.39 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $46.56 | 2021-2025 | Rexulti |
| Heartflow, INC. | $40.75 | 2025 | |
| Electromed, INC. | $34.65 | 2022-2024 | Smartvest |
| Biosense Webster, INC. | $33.15 | 2023 | Qdot Micro Catheter |
| Boston Scientific Corporation | $31.10 | 2019-2025 | General - Pain Management |
| Dexcom, INC. | $23.30 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $19.73 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.35 | 2022 | |
| Horizon Therapeutics Plc | $18.10 | 2023 | Krystexxa |
| Allergan, INC. | $17.67 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.45 | 2019 | |
| Pfizer INC. | $14.23 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Daley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.